Orbital Lymphoma

Jakobiec FA, Font RL. Orbit: lymphoid tumors. In: Spencer WH, Font RL, Green WR, et al, eds. Ophthalmic Pathology: An Atlas and Textbook. Vol. 3. 3rd ed. Philadelphia: WB Saunders; 1986:2663–2711.Google Scholar

Ellis JH, Banks PM, Campbell RJ, Liesegang TJ. Lymphoid tumors of the ocular adnexa: clinical correlation with the working formulation classification and immunoperoxidase staining of paraffin sections. Ophthalmology 1985;92:1311–1324.PubMedGoogle Scholar

Hornblass A, Jakobiec FA, Reifler DM, et al. Orbital lymphoid tumors located predominantly within extraocular muscles. Ophthalmology 1987;94:688–697.PubMedGoogle Scholar

Nikaido H, Mishima HK, Kiuchi Y, et al. Primary orbital malignant lymphoma: a clinicopathology study of 17 cases. Graefes Arch Clin Exp Ophthalmol 1991;229:206–209.PubMedCrossRefGoogle Scholar

Bairey O, Kremer I, Rokowsky E, et al. Orbital and adnexal involvement in systemic non-Hodgkin’s lymphoma. Cancer 1994;73:2395–2399.PubMedGoogle Scholar

Esmaeli B, Ahmadi MA, Manning J, et al. Clinical presentation and treatment of secondary orbital lymphoma. Ophthalmic Plast Reconstr Surg 2002;18:247–253.CrossRefGoogle Scholar

Mirabell R, Cella L, Weber D, et al. Optimizing radiotherapy of orbital and paraorbital tumors: intensity-modulated x-ray beams vs. intensity-modulated proton beams. Int J Radiat Oncol Biol Phys 2000;47:1111–1119.CrossRefGoogle Scholar

Letschert JG, Gonzalez DG, Koorneef L, et al. Results of radiotherapy in patients with stage I orbital non-Hodgkin’s lymphoma. Radiother Oncol 1991;22:36–44.PubMedCrossRefGoogle Scholar

Gordon LI, Harrington D, Anderson J, et al. Comparison of a second-generation combination chemotherapeutic regimen with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 1992;327:1342.PubMedCrossRefGoogle Scholar

Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002.PubMedCrossRefGoogle Scholar

Hagemeister FB, McLaughlin P, Swan F, et al. Prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood 1991;77:942.PubMedGoogle Scholar

Esmaeli B, Murray JL, Ahmadi MA, et al. Immunotherapy for low-grade non-Hodgkin’s secondary lymphoma of the orbit. Arch Ophthalmol 2002;120:1225–1227.PubMedGoogle Scholar

Syed NA, Albert DM. Surgical pathology of ophthalmic plastic surgery. In: Albert DM, ed. Ophthalmic Surgery: Principles and Techniques. Edinburgh: Blackwell Science; 1999:1648–1658.Google Scholar

Rosai J. In: Rosai J, ed. Ackerman’s Surgical Pathology. 8th ed. St Louis: CV Mosby; 1996:1–12, 29–62.Google Scholar

Jakobiec FA, McLean I, Font R. Clinicopathologic characteristics of orbital lymphoid hyperplasia. Symp Orbital Dis 1979;86:948–966.Google Scholar

Freedman AS, Nadler LM. Non-Hodgkin’s lymphomas. In: Bast RC, Kufe DW, Pollock RE, et al, eds. Cancer Medicine. 5th ed. New York: BC Decker; 2000: Sec 36, Ch 130.Google Scholar

Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.PubMedGoogle Scholar

Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998;16:2780–2795.PubMedGoogle Scholar

Bennett CL, Putterman A, Bitran JD, et al. Staging and therapy of orbital lymphomas. Cancer 1986;57:1204–1208.PubMedGoogle Scholar

Carr R, Barrington S, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340–3346.PubMedGoogle Scholar

Smitt MC, Donaldson SS. Radiotherapy is successful treatment for orbital lymphoma. Int J Radiat Oncol Biol Phys 1993;26:59–66.PubMedGoogle Scholar

Esik O, Ikeda H, Mukai K, Kaneko A. A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin’s lymphomas. Radiother Oncol 1996;38:13–18.PubMedCrossRefGoogle Scholar

Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998;339:21–26.PubMedCrossRefGoogle Scholar

Bessell EM, Henk JM, Wright JE, et al. Orbital and conjunctival lymphoma treatment and prognosis. Radiother Oncol 1988;13:237–244.PubMedCrossRefGoogle Scholar

Minehan KJ, Martenson JA, Garrity JA, et al. Local control and complications after radiation therapy for primary orbital lymphoma: a case for low-dose treatment. Int J Radiat Oncol Biol Phys 1991;20:791–796.PubMedGoogle Scholar

Bolek TW, Moyses HM, Marcus RB, et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 1999;44:31–36.PubMedCrossRefGoogle Scholar

Henk JM, Whitelocke RAF, Warrington AP, et al. Radiation dose to the lens and cataract formation. Int J Radiat Oncol Biol Phys 1993;25:815–820.PubMedGoogle Scholar

Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001;59:139–144.PubMedCrossRefGoogle Scholar

Dearnaly DF, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 1999;353:267–272.CrossRefGoogle Scholar

Cabanillas F, Rodriguez-Diaz PJ, Hagemeister FB, et al. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol 1998;9:511–518.PubMedCrossRefGoogle Scholar

Longo DL, Glatstein E, Duffey PL, et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989;7:1295–1302.PubMedGoogle Scholar

Khouri I, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803–3809.PubMedGoogle Scholar

McLaughlin P, Grillo-Lopez AJ, Liink BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.PubMedGoogle Scholar

Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997;90:2188–2195.PubMedGoogle Scholar

Maloney D, Smith B, Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 antibody (Mab) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin’s lymphoma cell lines. Blood 1996;88(suppl):637.Google Scholar

Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548–551.PubMedGoogle Scholar

Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457–470.PubMedGoogle Scholar

Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevvalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000;27:766–777.PubMedCrossRefGoogle Scholar